Pharmacokinetic assessments 
BLOOD
Blood samples for single-dose PK evaluations (Parts A, D, F, and H) were collected at predose and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h postdose and at day 5 follow-up (96 h). Blood samples for MAD evaluations (Part E) were collected on day 1 (predose and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose), day 2 to day 13 (predose), day 14 (predose and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose), day 15 (24 h post last dose), day 16 (48 h post last dose), and day 17 (72 h post last dose). To determine the concentrations of dersimelagon and dersimelagon glucuronide (a primary in vitro human metabolite), plasma samples were analyzed using a validated liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) method with solid phase extraction with a lower limit of quantification (LLOQ) of 0.1 ng/mL. The plasma PK parameters, including maximum observed plasma concentration (C